retatrutide a1c More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Dosing Guide: 1-12 mg

GLP-1 gastroparesis affects 4-fold more patients than placebo groups , with non-diabetic users facing 3.33 times higher risk than alternative weight loss treatments Short-acting GLP-1s cause more severe gastric slowing than long-acting versions , delaying emptying by 52 minutes versus 25 minutes respectively Retained gastric contents occur in 13.6% of GLP-1 users versus 2.3% of non-users , creating dangerous aspiration risks during medical procedures Most GLP-1 gastroparesis cases are reversible through tachyphylaxis , with gastric emptying effects diminishing within 4-6 weeks of continuous use Pre-procedural fasting protocols must be extended for GLP-1 users , holding daily medications on procedure day and weekly doses seven days before surgery The condition requires careful differentiation from functional dyspepsia and mechanical obstruction, as proper diagnosis directly impacts treatment outcomes

And the sooner you understand those pathways, the sooner you can stop blaming yourself for feeling weaker in the gym

Examples include: Wegovy (semaglutide) approved for chronic weight management Ozempic (semaglutide) commonly used to treat type 2 diabetes Mounjaro (tirzepatide) commonly used for diabetes treatment By influencing how your body regulates hunger and satiety, GLP-1 medications help you feel satisfied sooner and stay full for longer

Figure 2 Pharmacokinetics The pharmacokinetics in healthy volunteers and patients with T2D are comparable (57)

Yet unlike hypertension or high cholesterol, it remains deeply stigmatizedespecially for women